NCT06755333

Brief Summary

This study assessed the effectiveness of a preventive protocol that included oral hygiene measures, patient education, and motivational strategies in individuals eligible for hematopoietic stem cell transplantation (HSCT).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
35

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2023

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 9, 2023

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 29, 2023

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2024

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

December 18, 2024

Completed
14 days until next milestone

First Posted

Study publicly available on registry

January 1, 2025

Completed
Last Updated

January 1, 2025

Status Verified

December 1, 2024

Enrollment Period

9 months

First QC Date

December 18, 2024

Last Update Submit

December 24, 2024

Conditions

Keywords

Hematopoietic Stem Cell TransplantationDental ProphylaxisOral HygieneMotivation

Outcome Measures

Primary Outcomes (5)

  • PPD

    probing pocket depth (PPD) was measured as the distance from the free gingival margin to the bottom of the pocket by inserting a periodontal probe parallel to the longitudinal axis of the tooth using a periodontal probe (UNC 15, Hu-Friedy, Chicago, IL, USA) and a calibrated pressure of 0.3 N. All measurements were rounded to the nearest millimetre.

    measured at enrolment (T0) and 9 days after engraftment (T1)

  • FMBS

    Full Mouth Bleeding Score (FMBS) was measured dichotomously after periodontal probing. The mean bleeding score was indicated as percentage of sites detected positive for bleeding on the total number of sites

    measured at enrolment (T0) and 9 days after engraftment (T1)

  • FMPS

    Full Mouth Plaque Score (FMPS) was assessed the presence or absence of plaque on each tooth surface. The presence of plaque was evaluated as 1, while the absence as 0, on 6 sites per tooth (distobuccal, buccal, mesiobuccal, distolingual, lingual, mesiolingual). Mean plaque score was indicated as percentage of sites found positive for the presence of plaque on the total number of sites

    measured at enrolment (T0) and 9 days after engraftment (T1)

  • CI

    Calculus Index was measured using a probe and considering supragingival and subgingival calculus separately, with score 0 assigned in the absence of calculus and score 3 assigned to supragingival calculus exceeding two-thirds of the crown and/or continuous bands of subgingival calculus

    measured at enrolment (T0) and 9 days after engraftment (T1)

  • PRESENCE OF MUCOSITIS

    Presence of mucositis was evaluated as the presence of mucosal erythema or ulceration for 8 oral sites and assigning a score from 0 (normal oral mucosa) to 5 (\>3 sites of ulceration).

    measured 9 days after engraftment (T1)

Interventions

the patient underwent a professional oral hygiene session before starting chemotherapy, as part of the routine pre-transplant procedure. Patients then received oral hygiene instructions.

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients undergoing autologous hematopoietic stem cell transplantation (HSCT) for hematologic diseases. The study included patients treated at the Hematology Unit of Pisa University Hospital. Participants were selected based on their eligibility for HSCT and their consent to participate in the study

You may qualify if:

  • male or female patients
  • aged 18-75 years
  • patients scheduled for HSCT
  • acceptance of study participation
  • compliance to follow-up

You may not qualify if:

  • \- denial of the consent to participate in the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University Hospital of Pisa

Pisa, Italy

Location

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Researcher at the Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine of the University of Pisa, Principal Investigator

Study Record Dates

First Submitted

December 18, 2024

First Posted

January 1, 2025

Study Start

January 9, 2023

Primary Completion

September 29, 2023

Study Completion

May 31, 2024

Last Updated

January 1, 2025

Record last verified: 2024-12

Data Sharing

IPD Sharing
Will not share

Locations